Free Trial

Iradimed Q1 2023 Earnings Report

Iradimed logo
$52.41 -0.97 (-1.82%)
As of 04:00 PM Eastern

Iradimed EPS Results

Actual EPS
$0.27
Consensus EPS
$0.25
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Iradimed Revenue Results

Actual Revenue
$15.48 million
Expected Revenue
$14.76 million
Beat/Miss
Beat by +$720.00 thousand
YoY Revenue Growth
N/A

Iradimed Announcement Details

Quarter
Q1 2023
Time
N/A
Remove Ads

Iradimed Earnings Headlines

A market crash is coming—here’s when
The stock market cycle I've used to identify the most likely day of the next market crash is the exact same indicator that helped me call the bear market of 2018... the bull market in 2020... the bear market in 2022... the roaring bull markets in 2023 and 2024... and more. I'm convinced it has helped me identify the next big crash too. We are at an important juncture in the markets. Knowing what to do in the months to come is critical.
iRadimed price target raised to $72 from $60 at Roth MKM
See More Iradimed Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Iradimed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Iradimed and other key companies, straight to your email.

About Iradimed

Iradimed (NASDAQ:IRMD) Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.

View Iradimed Profile

More Earnings Resources from MarketBeat